GenSci139 / GeneScience - LARVOL DELTA

GenSci139-101: GenSci139 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=280 | Recruiting | Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • Oncology • Solid Tumor

GenSci139 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=280 | Not yet recruiting | Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.

First-in-human • New P1 trial • Oncology • Solid Tumor

GenSci139: A highly differentiated and potential best-in-class EGFRxHER2 bispecific ADC, in multiple solid tumors (ESMO 2025) - "Background ENHERTU®, a HER2-targeting ADC, has been approved for the treatment in multiple indications, yet significant unmet needs persist in HER2-low settings beyond breast cancer. These results position GenSci139 as a promising therapeutic candidate for further clinical development in NSCLC, GC, TNBC and other EGFR/HER2-driven malignancies. Legal entity responsible for the study GeneScience Pharmaceutical Co., Ltd."

IO biomarker • Breast Cancer • Gastric Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • EGFR • HER-2

GenSci139, a highly differentiated EGFR×HER2 bispecific ADC, for the treatment of multiple solid tumors (AACR 2025) - "These data suggest the potential of GenSci139 as a novel and effective therapy across a variety of tumor types, including urothelial cancer, lung cancer, gastric cancer, colorectal cancer, ovarian cancer, breast cancer, etc., and support its further evaluation in IND-enabling studies."

IO biomarker • Breast Cancer • Colorectal Cancer • Gastric Cancer • Genito-urinary Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • Urothelial Cancer • EGFR • HER-2